# Source and claim audit, 5 September 2026

## Literature scope

Targeted primary-source searches covered AnAge maturation/development/longevity, DrugAge central/maximum endpoint relationships, database licensing and release documentation, and recent methodological critiques. Broad hypotheses already exist in de Magalhães et al. 2007 and Barardo et al. 2017; papers therefore make no first-discovery claim. Search was targeted, not systematic or exhaustive. Searches stopped after provenance, prior art, central limitations and prespecified sample checks were established. No claim of exhaustive novelty clearance is made.

| Claim | Primary support | Assessment |
|---|---|---|
| HAGR data permit attributed research and commercial reuse | https://genomics.senescence.info/legal.html | Official CC BY 3.0 terms read; current citation points to 2024 NAR paper |
| AnAge developmental timing was studied previously using phylogenetic contrasts | https://pubmed.ncbi.nlm.nih.gov/17339640/ | Verified title, authors, DOI, abstract; current analysis does not reproduce a phylogenetic model |
| Longevity records depend on observation effort and provenance | https://genomics.senescence.info/help.html | Official definitions of sample-size, quality and specimen origin read |
| AnAge export count differs from release total | Frozen raw export and https://genomics.senescence.info/species/release.html | Both R and Python count 4,645; release says 4,671; cause unresolved |
| DrugAge endpoint correlation studied previously | https://pmc.ncbi.nlm.nih.gov/articles/PMC5418190/ and doi:10.1111/acel.12585 | Primary article describes correlated central/maximum changes; current estimand is paired disagreement with source-balanced weighting |
| DrugAge selection favors lifespan-extending compounds | Same 2017 primary article | Selection caveat is central to manuscript; no population-wide efficacy claim |
| Reporting/selection problems merit caution | Parish et al. 2025 https://www.nature.com/articles/s41514-025-00287-0 | Article title, full authors, 27 November 2025 publication and article 96 verified; no figures or copyrighted passages copied |
| Central field uses median when available | https://genomics.senescence.info/help.html | Official description; cannot standardize retrospectively with this export |
| Mouse maximum can mean 90th percentile | Harrison et al. 2014, PMID 24245565 | Explicit primary abstract; therefore use maximum/upper-tail terminology |

## Prespecified sampled AnAge consistency checks

Selected first, middle and last alphabetically among the 801 included species. Live HAGR entry values match the frozen export:

| Species | Female maturity, days | Adult mass, g | Longevity, years | Source |
|---|---:|---:|---:|---|
| Acinonyx jubatus | 456 | 53500 | 20.5 | https://www.genomics.senescence.info/species/entry.php?species=Acinonyx_jubatus |
| Macaca sinica | 1460 | 4370 | 29.3 | https://www.genomics.senescence.info/species/entry.php?species=Macaca_sinica |
| Zapus hudsonius | 61 | 18 | 5.6 | https://www.genomics.senescence.info/species/entry.php?species=Zapus_hudsonius |

Two pages were retrieved with Python when browser retrieval failed. These checks are **database consistency checks**, not independent extraction from Weigl 2005 or other original monographs. Every raw record's reference identifiers remain in the export.

## DrugAge bibliography and sample audit

NCBI ESummary metadata were obtained in one batch for all 248 included keys. All returned titles. Inspection found one obvious unrelated title: 101039. The supplemental bibliography flags that key rather than falsely citing the unrelated paper. Original NCBI response is preserved for provenance. Remaining titles being broadly relevant does not establish correct extraction of every dose or endpoint.

- **101039**, first key numerically: two 2-Selenium-bridged-beta-cyclodextrin entries, central changes 8.69 and 7.24, maximum 4.76 for both. PubMed 101039 is an unrelated computed-tomography article. A candidate relevant study is *2-SeCD treatment extends lifespan, improves healthspan and enhances resistance to stress in Caenorhabditis elegans*, RSC Advances (2017), DOI 10.1039/C7RA07210D. Search located the primary article; full numeric table retrieval was not successful. **Unresolved extraction.** Planned result retained, documented post-hoc exclusion gives −2.7681 points, CI −3.9908 to −1.5848. Do not describe this candidate link as a verified correction.
- **24245565**, middle key: Harrison et al. 2014. The primary PubMed abstract reports acarbose male/female central changes 22%/5% and maximum (90th percentile) changes 11%/9%, matching the export. Six rows belong to this source. We did not re-extract every number.
- **38753230**, last key: Miller et al. 2024, GeroScience 46:4657–4670, DOI 10.1007/s11357-024-01176-2, PMCID PMC11336000. Primary manuscript available from https://escholarship.org/uc/item/7tk5p1jw . Checked central gains of 15% for male 16-hydroxyestriol and 14% for male late-start canagliflozin agree. DrugAge calls the former 16-alpha-hydroxyestradiol, a label discrepancy explicitly retained and disclosed; no compound-specific recommendation is made. Source table values can be more precise than the rounded export. Full 18-row re-extraction was not completed.

## Numerical and output checks

Independent raw parsing and least squares/cluster-sandwich calculations in Python/NumPy agree with R. Independent RNG bootstrap yields a closely similar DrugAge interval. Student p values checked by direct tail integration. SHA-256 input hashes verified. All 10 PDF pages and all four figures were visually inspected; final HTML is structurally checked for headings, alt text and local links. PDFs are not tagged, so accessible HTML is also supplied. Any publication on WordPress must be verified by the website task after integration; these local checks do not verify a live deployment.
